Formulation Development
Tyligand Bioscience & Context Therapeutics Sign Strategic Development Agreement for Onapristone ER
Tyligand Bioscience and Context Therapeutics LLC recently announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of….
Nurix Therapeutics Closes $120-Million Financing to Advance Targeted Protein Modulation Drug Pipeline
With the funds raised in this financing, Nurix is well positioned to bring its targeted protein modulation therapeutics into the clinic…..
Zydus & XOMA Announce Exclusive Licensing Agreement
Zydus Cadila and XOMA Corporation recently announced they have entered into a licensing agreement to advance an IL-2-based immuno-oncology (IO) drug candidate that….
DEINOVE Passes Second Milestone of the AGIR Program
DEINOVE recently announced it has successfully completed the second key milestone of the AGIR program – Antibiotics against Resistant Infectious Germs – which is supported by……
Ajinomoto Bio-Pharma Services Announces Formation of External Advisory Board
Ajinomoto Bio-Pharma Services recently announced the formation of its External Advisory Board (EAB) to provide insight into industry trends and…..
BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections, Including COVID-19
BeyondSpring Inc. recently announced the submission of a provisional US patent application for its pipeline asset BPI-002, for methods of treating viral infections, including COVID-19,…
Menlo Therapeutics & Foamix Pharmaceuticals Complete Merger
Menlo Therapeutics Inc. recently announced the completion of its merger with Foamix Pharmaceuticals Ltd. following the satisfaction of all closing conditions required by the merger…
Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 Study
Retrophin, Inc. recently announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating the safety and efficacy of…
10 Drugs in Pre-Registration Phase Have Potential to Reach Blockbuster Status by 2025
Out of all the drugs that are currently in the pre-registration phase and are expected to launch in 2020, 10 have the potential to reach…
Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment & Prevention of Coronavirus Disease
Emergent BioSolutions Inc. recently announced it has initiated development of two product candidates for the treatment and prevention of coronavirus disease (COVID-19). These product candidates…
Beroni Group Advances Research & Development of Medical Solution for Coronavirus (COVID-19)
Beroni Group recently announced its development of a medical solution using nanobody technology for the novel coronavirus (COVID-19) in collaboration with Tianjin University in China…
Arcturus Therapeutics & Duke-NUS Medical School Partner to Develop a COVID-19 Vaccine
Arcturus Therapeutics and Duke-NUS Medical School (Duke-NUS) recently announced their partnership to develop a Coronavirus….
PDC*line Pharma Announces First Patient Dosed With its Therapeutic Cancer Vaccine
PDC*line Pharma recently announced the first patient was dosed with its innovative medicinal product candidate PDC*lung01 in a Phase 1/2 trial in….
zPREDICTA Enters Strategic Collaboration With LabCorp
zPREDICTA, Inc. recently announce it has entered into a strategic collaboration with LabCorpto to support the adoption of….
ADMA Biologics Highlights Expanded Intellectual Property Portfolio
ADMA Biologics recently announced that it has received another Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent application related to its…..
Evelo Biosciences Announces Biomarker Data Showing Drug is Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases
Evelo Biosciences, Inc. recently announced biomarker data for EDP1815, its lead inflammation product candidate. Interim data from individuals in the ongoing Phase 1b clinical trial…
SPECIAL FEATURE - Improving Bioavailability & Solubility: Understand Your Molecule
Contributor Cindy H. Dubin asked several leading companies about how they are currently overcoming today’s most pressing bioavailability and solubility challenges for their pharma clients.
INTRATUMORAL DELIVERY - Combining Local & Systemic Treatments: Could Immuno-Oncology Finally Enable Local Intratumoral Delivery?
Lewis H. Bender, MA, MBA, says cancer is a local and systemic disease, and new forms of local treatment, such as intratumoral dosing coupled with systemic immunotherapy, are being explored.
DEVELOPMENT TIMELINES - Drug Development Times, What it Takes - Part 2
Josef Bossart, PhD, reviews the Development and Review Times associated with new molecular entity (NME) approvals throughout the 2010 to 2018 period.
EXECUTIVE INTERVIEW - Noxopharm: Introducing a Novel & Potentially Transformative Drug Candidate in the Treatment of Cancer
Graham Kelly, Founder, Executive Chairman, and CEO of Noxopharm, discusses the company’s innovative approach to cancer treatment.
